BTIG Research Forecasts Strong Price Appreciation for Enovis (NYSE:ENOV) Stock

Enovis (NYSE:ENOV) had its price target raised by investment analysts at BTIG Research from $36.00 to $42.00 in a research note issued on Thursday, Marketbeat reports. The firm presently has a “buy” rating on the stock. BTIG Research‘s target price suggests a potential upside of 54.64% from the company’s current price.

ENOV has been the subject of a number of other reports. Zacks Research upgraded shares of Enovis from a “strong sell” rating to a “hold” rating in a research report on Wednesday, July 29th. Citigroup reissued a “market outperform” rating on shares of Enovis in a research note on Wednesday, September 2nd. Wall Street Zen upgraded shares of Enovis from a “hold” rating to a “buy” rating in a research report on Saturday, October 31st. BMO Capital Markets set a $27.00 price objective on Enovis in a report on Tuesday, September 1st. Finally, Weiss Ratings upgraded Enovis from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday. Ten equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $38.62.

Enovis Price Performance

ENOV stock traded down $1.46 during mid-day trading on Thursday, reaching $27.16. 2,304,734 shares of the company’s stock were exchanged, compared to its average volume of 1,449,886. The company has a debt-to-equity ratio of 0.84, a current ratio of 1.98 and a quick ratio of 1.00. Enovis has a 12-month low of $16.70 and a 12-month high of $32.41. The stock’s 50 day moving average is $19.91 and its 200 day moving average is $23.09. The company has a market cap of $1.57 billion, a price-to-earnings ratio of -2.95 and a beta of 1.31.

Enovis (NYSE:ENOV) last posted its quarterly earnings data on Thursday, November 5th. The company reported $0.88 EPS for the quarter, beating analysts’ consensus estimates of $0.77 by $0.11. Enovis had a positive return on equity of 12.03% and a negative net margin of 47.96%. The business had revenue of $558.73 million during the quarter, compared to analysts’ expectations of $557.12 million. During the same period in the previous year, the business earned $0.75 earnings per share. The business’s revenue was up 1.8% compared to the same quarter last year. On average, research analysts expect that Enovis will post 3.15 EPS for the current year.

Insider Transactions at Enovis

In other news, insider Oliver Engert acquired 5,140 shares of the business’s stock in a transaction that occurred on Thursday, September 3rd. The stock was purchased at an average cost of $19.46 per share, for a total transaction of $100,024.40. Following the completion of the transaction, the insider owned 61,238 shares in the company, valued at approximately $1,191,691.48. This trade represents a 9.16% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Damien Mcdonald purchased 13,035 shares of the business’s stock in a transaction dated Friday, September 4th. The shares were purchased at an average price of $19.15 per share, with a total value of $249,620.25. Following the acquisition, the chief executive officer directly owned 247,077 shares in the company, valued at approximately $4,731,524.55. The trade was a 5.57% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders have purchased 23,293 shares of company stock worth $449,599 over the last 90 days. 2.90% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Enovis

Institutional investors and hedge funds have recently made changes to their positions in the stock. Maryland State Retirement & Pension System acquired a new stake in Enovis in the 3rd quarter valued at approximately $238,000. Illinois Municipal Retirement Fund lifted its stake in Enovis by 22.4% during the third quarter. Illinois Municipal Retirement Fund now owns 38,366 shares of the company’s stock worth $701,000 after purchasing an additional 7,028 shares in the last quarter. Private Management Group Inc. lifted its stake in Enovis by 31.3% during the third quarter. Private Management Group Inc. now owns 1,792,429 shares of the company’s stock worth $32,748,000 after purchasing an additional 427,347 shares in the last quarter. Fulcrum Asset Management LLP boosted its position in shares of Enovis by 2,739.4% during the third quarter. Fulcrum Asset Management LLP now owns 20,330 shares of the company’s stock worth $375,000 after buying an additional 19,614 shares during the period. Finally, Villanova Investment Management Co boosted its position in shares of Enovis by 10.2% during the third quarter. Villanova Investment Management Co now owns 148,424 shares of the company’s stock worth $2,712,000 after buying an additional 13,740 shares during the period. 98.45% of the stock is owned by hedge funds and other institutional investors.

Key Enovis News

Here are the key news stories impacting Enovis this week:

• Positive Sentiment: Q3 adjusted earnings were $0.88 per share, beating estimates of about $0.77 and topping $0.75 a year earlier. Revenue of $558.7 million slightly exceeded forecasts and grew 1.8% year over year. Enovis Q3 2026 results
• Positive Sentiment: Enovis raised its 2026 EPS guidance to $3.58–$3.79, signaling improved earnings expectations. Guidance and repurchase announcement
• Positive Sentiment: The company authorized a $200 million share-repurchase program, which could support per-share results and signal confidence in its prospects. Share-buyback announcement
• Positive Sentiment: Wells Fargo raised its target to $37 and maintained an Overweight rating; Needham lifted its target to $38 and BTIG to $42, both with Buy ratings. Wells Fargo analyst rating
• Neutral Sentiment: Canaccord lowered its price target from $45 to $42 but kept a Buy rating. Reports also highlighted product innovation and market-share gains, though market volatility remains a factor. Product innovation and share gains

About Enovis

Enovis Corporation (NYSE: ENOV) is a medical technology company that develops, manufactures and distributes products designed to improve patient recovery, mobility and quality of life. Its portfolio serves orthopedic, sports medicine, physical therapy and rehabilitation markets, as well as other areas of musculoskeletal care.

The company’s products include orthopedic implants and surgical technologies, braces and supports, cold and compression therapy systems, electrotherapy and rehabilitation equipment, and other solutions used by hospitals, surgeons, physical therapists, athletic trainers and patients.